Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

By Jian Li, Roger L. Nation, J. Turnidge, R. Milne, K. Coulthard, C. Rayner, David L. Paterson. Lancet. Infectious Diseases (Print), 2006

1,327 citations recorded by the source corpus.

Subfields: Molecular Medicine, Pharmacology, Pollution

View Paper: https://www.semanticscholar.org/paper/5a32dda346379b87c71f5dad9466a65bcc7480cf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Medicine

1. P. Nordmann
2. L. Poirel
3. David L. Paterson
4. H. Seifert
5. Jian Li
6. Trish Perl
7. Anton Y. Peleg
8. Roger L. Nation

In Pharmacology

1. H. Seifert
2. P. Nordmann
3. L. Poirel
4. Alan Forrest
5. F. Silveira
6. Jian Li
7. Trish Perl
8. S. Shoham

In Pollution

1. P. Nordmann
2. L. Poirel
3. L. Maragakis
4. F. Codjoe
5. E. Donkor

Citations in the corpus

• Nonribosomal peptides synthetases and their applications in industry (2016, neutral): “aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae [61, 64].”
• Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. (2007, background): “Nephrotoxicity and neurotoxicity are the most common potential toxicities with parenteral administration of polymyxins.(12,69) However, the toxicity observed in early clinical studies with colistimethate sodium was almost certainly due to a lack of understanding of its pharmacokinetics, pharmacodyna”
• Acinetobacter baumannii: Emergence of a Successful Pathogen (2008, background): “There are two commercially available forms of colistin, namely, colistin sulfate for oral and topical use, and CMS, also known as sodium colistin methanesulfonate or colistin sulfomethate sodium, for parenteral use (332).”
• Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production (2010, background): “In these multidrug-resistant (MDR) strains, colistin (also known as polymyxin E) is often the only remaining treatment (15), although colistin-resistant clinical isolates have already been reported (7, 10, 21).”
• Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. (2007, background): “Among the various therapeutic alternatives, colistin has received renewed interest [119].”
• Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes (2017, background): “content and ultimately causing cell death (4, 13).”
• Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. (2008, methodology): “Colistin is bactericidal against Acinetobacter species, and its effect is concentration dependent [95].”
• Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients (2011, background): “In renally healthy individuals, the prodrug, CMS, is predominantly cleared by renal excretion, with only a relatively small fraction of a dose converted to the active antibacterial, colistin (23, 26); thus, total clearance of CMS is expected to decline with CrCL.”